
Haemonetics (HAE) Stock Forecast & Price Target
Haemonetics (HAE) Analyst Ratings
Bulls say
Haemonetics is a global company with two core business units: Apheresis (Plasma and Blood Center) and MedSurg (Blood Management and Interventional Technologies). The company has been shifting its revenue base towards the MedSurg segment through acquisitions, which is now its largest business segment. With new product launches and potential growth in the Plasma and Hospital businesses, we expect continued profitability and potential for best-in-class margins among MedTech peers. Recent commercial stumbles have led to scrutiny in the Interventional Technologies sub-segment but the company has potential for sustained sales growth through new products and potential M&A.
Bears say
Haemonetics is facing strong competition in the blood center segment, potentially limiting growth potential in this area. Furthermore, the decline in the interventional technologies business and lack of significant growth in the hospital segment raises concerns about the company's future financial performance. With the company's reliance on disposable products and current challenges in sales strategy, the negative outlook for Haemonetics's stock is justified.
This aggregate rating is based on analysts' research of Haemonetics and is not a guaranteed prediction by Public.com or investment advice.
Haemonetics (HAE) Analyst Forecast & Price Prediction
Start investing in Haemonetics (HAE)
Order type
Buy in
Order amount
Est. shares
0 shares